1. Home
  2. WBX vs BMEA Comparison

WBX vs BMEA Comparison

Compare WBX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wallbox N.V.

WBX

Wallbox N.V.

HOLD

Current Price

$3.01

Market Cap

118.0M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.43

Market Cap

98.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WBX
BMEA
Founded
2015
2017
Country
Spain
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.0M
98.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WBX
BMEA
Price
$3.01
$1.43
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$9.00
$8.71
AVG Volume (30 Days)
34.2K
1.2M
Earning Date
02-26-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$174,593,453.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$37.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.30
$0.87
52 Week High
$12.30
$4.59

Technical Indicators

Market Signals
Indicator
WBX
BMEA
Relative Strength Index (RSI) 52.35 54.08
Support Level $2.84 $1.31
Resistance Level $3.13 $1.66
Average True Range (ATR) 0.17 0.12
MACD 0.05 0.00
Stochastic Oscillator 85.54 47.13

Price Performance

Historical Comparison
WBX
BMEA

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: